We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 25, 2021

Zanubrutinib for Relapsed/Refractory Mantle Cell Lymphoma

Blood advances


Additional Info

Blood advances
Zanubrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Blood Adv 2021 Jun 22;5(12)2577-2585, CS Tam, S Opat, D Simpson, G Cull, J Munoz, TJ Phillips, WS Kim, S Rule, SK Atwal, R Wei, W Novotny, J Huang, M Wang, J Trotman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading